Original article
Vol. 155 No. 9 (2025)
PharmVisit: Reducing medication-related problems through an interprofessional ward round process in acute geriatric care – a quality improvement project
-
Cite this as:
-
Swiss Med Wkly. 2025;155:4351
-
Published
-
24.09.2025
Summary
STUDY AIMS: Older adult patients admitted to hospital are often multimorbid, polymedicated and thus more susceptible to medication-related problems. To improve medication safety for this patient population, the University Hospital of Bern’s Department of Geriatrics hosts clinical pharmacists on its ward rounds as part of an interprofessional collaboration project called PharmVisit. This study aimed to describe the interventions recommended by those clinical pharmacists and their rates of acceptance by physicians.
METHODS: The PharmVisit pilot project involved geriatricians and clinical pharmacists separately preparing for weekly ward rounds. Pharmacists used a checklist for medication reviews and the Swiss Association of Public Health Administration and Hospital Pharmacists (GSASA) classification tool for characterisation of recommendations. All patients residing on the ward during the study period were included. Outside the patient’s room, clinicians and pharmacists, accompanied by a nurse, discussed the ongoing drug therapy and recommended beneficial medication adjustments resulting from the re-evaluation of treatment indications, potential drug-drug interactions, dose adjustments, optimised dosages and forms of administration, and medication omissions. Afterwards, all the parties, including the patient, discussed the medication changes at the bedside. Type and number of recommendations by clinical pharmacists were tabulated as primary outcomes. Acceptance rate as a secondary outcome was calculated based on the number of pharmacists’ recommendations compared to the number of prescriptions adapted directly during ward rounds.
RESULTS: From July 2023 to April 2024, 46 ward rounds were documented, resulting in 480 recommended interventions for 221 patients. The top reasons for recommending interventions, categorised according to the GSASA tool, were dosing issues (17%), medication omissions (15%) and no apparent indication (13%). Clinical pharmacists made the most recommendations on issues involving pain medication (analgesics and opioids, 4% and 2%, respectively), laxative drugs (4%), proton-pump inhibitors (4%), hypnotics and sedatives (2%), and drugs for obstructive airway diseases (2%), reflecting the most problematic drugs identified in studies nationally and internationally.
The overall acceptance rate of PharmVisit recommendations was 54%. An additional 33% of recommended interventions were referred to a senior physician for a decision or to the primary care provider in the discharge letter. The most frequently and directly accepted intervention recommendations were optimising administration modalities (77%), medication exchange or substitution (71%) and medication discontinuation (62%).
CONCLUSION: This project emphasised how including clinical pharmacists in interprofessional ward round teams enabled the integration and consideration of more viewpoints on different aspects of drug therapies, facilitating a more critical debate on medication therapy decisions. Because older adult patients are at an elevated risk of medication-related problems, especially the high acceptance rate of deprescribing, recommendations suggest that PharmVisit is a meaningful means of reducing potentially inappropriate medications.
References
- 1. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004 Jan;57(1):6–14. 10.1046/j.1365-2125.2003.02007.x
- 2. Vandergrift JL, Weng W, Leff B, Gray BM. Geriatricians, general internists, and potentially inappropriate medications for a national sample of older adults. J Am Geriatr Soc. 2024 Jan;72(1):37–47. 10.1111/jgs.18489
- 3. Hanlon JT, Semla TP, Schmader KE. Alternative Medications for Medications in the Use of High-Risk Medications in the Elderly and Potentially Harmful Drug-Disease Interactions in the Elderly Quality Measures. J Am Geriatr Soc. 2015 Dec;63(12):e8–18. 10.1111/jgs.13807
- 4. Fishman L, Brühwiler L, Schwappach D. [Medication safety in Switzerland: where are we today?]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Sep;61(9):1152–8. 10.1007/s00103-018-2794-z
- 5. Giannini O, Rizza N, Pironi M, Parlato S, Waldispühl Suter B, Borella P, et al. Prevalence, clinical relevance and predictive factors of medication discrepancies revealed by medication reconciliation at hospital admission: prospective study in a Swiss internal medicine ward. BMJ Open. 2019 May;9(5):e026259. 10.1136/bmjopen-2018-026259
- 6. Guignard B, Bonnabry P, Perrier A, Dayer P, Desmeules J, Samer CF. Drug-related problems identification in general internal medicine: the impact and role of the clinical pharmacist and pharmacologist. Eur J Intern Med. 2015 Jul;26(6):399–406. 10.1016/j.ejim.2015.05.012
- 7. Blum MR, Sallevelt BT, Spinewine A, O’Mahony D, Moutzouri E, Feller M, et al. Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM): cluster randomised controlled trial. BMJ. 2021 Jul;374(1585):n1585. 10.1136/bmj.n1585
- 8. Griese-Mammen N, Hersberger KE, Messerli M, Leikola S, Horvat N, van Mil JW, et al. PCNE definition of medication review: reaching agreement. Int J Clin Pharm. 2018 Oct;40(5):1199–208. 10.1007/s11096-018-0696-7
- 9. Hanlon JT, Schmader KE. The Medication Appropriateness Index: A Clinimetric Measure. Psychother Psychosom. 2022;91(2):78–83. 10.1159/000521699
- 10. Maes KA, Tremp RM, Hersberger KE, Lampert ML; GSASA Working group on clinical pharmacy. Demonstrating the clinical pharmacist’s activity: validation of an intervention oriented classification system. Int J Clin Pharm. 2015 Dec;37(6):1162–71. 10.1007/s11096-015-0179-z
- 11. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. BMJ Qual Saf. 2016 Dec;25(12):986–92. 10.1136/bmjqs-2015-004411
- 12. Ye L, Yang-Huang J, Franse CB, Rukavina T, Vasiljev V, Mattace-Raso F, et al. Factors associated with polypharmacy and the high risk of medication-related problems among older community-dwelling adults in European countries: a longitudinal study. BMC Geriatr. 2022 Nov;22(1):841. 10.1186/s12877-022-03536-z
- 13. Reinau D, Furrer C, Stämpfli D, Bornand D, Meier CR. Evaluation of drug-related problems and subsequent clinical pharmacists’ interventions at a Swiss university hospital. J Clin Pharm Ther. 2019 Dec;44(6):924–31. 10.1111/jcpt.13017
- 14. Almanasreh E, Moles R, Chen TF. The medication reconciliation process and classification of discrepancies: a systematic review. Br J Clin Pharmacol. 2016 Sep;82(3):645–58. 10.1111/bcp.13017
- 15. Bourne RS, Jeffries M, Phipps DL, Jennings JK, Boxall E, Wilson F, et al. Understanding medication safety involving patient transfer from intensive care to hospital ward: a qualitative sociotechnical factor study. BMJ Open. 2023 May;13(5):e066757. 10.1136/bmjopen-2022-066757
- 16. Studer H, Imfeld-Isenegger TL, Beeler PE, Ceppi MG, Rosen C, Bodmer M, et al. The impact of pharmacist-led medication reconciliation and interprofessional ward rounds on drug-related problems at hospital discharge. Int J Clin Pharm. 2023 Feb;45(1):117–25. 10.1007/s11096-022-01496-3
- 17. Botros S, Dunn J. Implementation and spread of a simple and effective way to improve the accuracy of medicines reconciliation on discharge: a hospital-based quality improvement project and success story. BMJ Open Qual. 2019 Aug;8(3):e000363. 10.1136/bmjoq-2018-000363
- 18. Schneider R, Reinau D, Schwenkglenks M, Meier CR. Helsana Arzneimittelreport 2017. 2017. Available from: https://www.helsana.ch/ [last accessed: 30.05.2025].
- 19. The World Health Organization WHO. Global burden of preventable medication-related harm in health care: a systematic review. Geneva: 2024. Available from: https://www.who.int/ [last accessed: 30.05.2025]
- 20. Jermini M, Fonzo-Christe C, Blondon K, Milaire C, Stirnemann J, Bonnabry P, et al. Financial impact of medication reviews by clinical pharmacists to reduce in-hospital adverse drug events: a return-on-investment analysis. Int J Clin Pharm. 2024 Apr;46(2):496–505. 10.1007/s11096-023-01683-w
- 21. Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013 May;66(3):201–2. 10.4212/cjhp.v66i3.1261
- 22. Veronese N, Gallo U, Boccardi V, Demurtas J, Michielon A, Taci X, et al. Efficacy of deprescribing on health outcomes: an umbrella review of systematic reviews with meta-analysis of randomized controlled trials. Ageing Res Rev. 2024 Mar;95:102237. 10.1016/j.arr.2024.102237
- 23. Okafor CE, Keramat SA, Comans T, Page AT, Potter K, Hilmer SN, et al. Cost-Consequence Analysis of Deprescribing to Optimize Health Outcomes for Frail Older People: A Within-Trial Analysis. J Am Med Dir Assoc. 2024 Mar;25(3):539–544.e2. 10.1016/j.jamda.2023.12.016
- 24. Radcliffe E, Servin R, Cox N, Lim S, Tan QY, Howard C, et al. What makes a multidisciplinary medication review and deprescribing intervention for older people work well in primary care? A realist review and synthesis. BMC Geriatr. 2023 Sep;23(1):591. 10.1186/s12877-023-04256-8
- 25. Bülow C, Clausen SS, Lundh A, Christensen M. Medication review in hospitalised patients to reduce morbidity and mortality. Cochrane Database Syst Rev. 2023 Jan;1(1):CD008986. 10.1002/14651858.CD008986.pub4